Gout is driven by monosodium urate crystal deposition, but new research shows the disease involves broader metabolic and genetic networks.
A large multi-omics study analyzed data from over 1.5 million participants, identifying 32 metabolites, one lipid species, and two plasma proteins with causal links to gout risk. Triglyceride-rich lipoproteins and isoleucine were tied to higher risk, while ISLR2 and ITIH3 proteins showed protective effects.
Researchers mapped these biomarkers to tissue-specific gene activity in the kidney, liver, and blood, pinpointing PRELID1, NIPAL1, LMAN2, and CAD as high-confidence effector genes. Lab tests in macrophages confirmed dysregulation after inflammatory stimulation.
The findings reveal a causal chain from circulating metabolites to tissue-level gene changes, offering new targets for gout therapies beyond traditional urate-focused approaches.